IN2014DN09594A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09594A
IN2014DN09594A IN9594DEN2014A IN2014DN09594A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A IN 9594DEN2014 A IN9594DEN2014 A IN 9594DEN2014A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A
Authority
IN
India
Prior art keywords
ophthalmological
vehicle system
eye
cornea
active substance
Prior art date
Application number
Other languages
English (en)
Inventor
Ute Steinfeld
Frank Holzer
Hyeck Hee Lee
Markus Mahler
Original Assignee
F Holzer Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Holzer Gmbh filed Critical F Holzer Gmbh
Publication of IN2014DN09594A publication Critical patent/IN2014DN09594A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IN9594DEN2014 2012-05-15 2013-05-14 IN2014DN09594A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168139.9A EP2664329A1 (de) 2012-05-15 2012-05-15 Ophthalmologisches Vehikelsystem
PCT/EP2013/059927 WO2013171204A2 (de) 2012-05-15 2013-05-14 Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung

Publications (1)

Publication Number Publication Date
IN2014DN09594A true IN2014DN09594A (de) 2015-07-31

Family

ID=48463974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9594DEN2014 IN2014DN09594A (de) 2012-05-15 2013-05-14

Country Status (12)

Country Link
US (1) US20150139973A1 (de)
EP (2) EP2664329A1 (de)
JP (1) JP2015521182A (de)
KR (1) KR20150014966A (de)
CN (1) CN104394859A (de)
AU (1) AU2013261873A1 (de)
CA (1) CA2873265A1 (de)
HK (1) HK1202427A1 (de)
IN (1) IN2014DN09594A (de)
MX (1) MX2014013884A (de)
RU (1) RU2014145440A (de)
WO (1) WO2013171204A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2952209T (pt) * 2014-06-04 2018-05-09 Alfasigma Spa Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral
US10240112B2 (en) * 2014-06-06 2019-03-26 Archer Daniels Midland Company Microemulsions and their use in metal working fluids, wood stains, or wood sealers
CA2963872C (en) * 2014-10-09 2023-09-12 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
KR101984116B1 (ko) 2015-01-12 2019-05-31 켄달리온 테라퓨틱스 인코포레이티드 마이크로-액적 전달 장치 및 방법
WO2016164830A1 (en) 2015-04-10 2016-10-13 Lagunita Llc Piezoelectric dispenser with replaceable ampoule
WO2016181998A1 (ja) * 2015-05-12 2016-11-17 ライオン株式会社 眼科用組成物
EP3128007A1 (de) * 2015-08-07 2017-02-08 Gene Signal International SA Sterile emulsion mit einem stabilen phosphorothioat-oligonukleotid
WO2017025471A1 (en) * 2015-08-07 2017-02-16 Gene Signal International Sa Sterile emulsion comprising a stable phosphorothioate oligonucleotide
CN108430458B (zh) 2015-10-26 2022-05-10 哈佛学院院长等 还原和氧化的多糖及其使用方法
WO2018077958A1 (en) 2016-10-27 2018-05-03 Unilever N.V. A personal care composition comprising curcuminoids
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
CA3039106A1 (en) 2017-01-20 2018-07-26 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
CN107158020A (zh) * 2017-05-18 2017-09-15 德施普科技发展温州有限公司 一种眼科用药物组合物及其制备方法
JP7436363B2 (ja) 2017-12-08 2024-02-21 ノバルティス アーゲー 流体送達アライメントシステム
KR102094882B1 (ko) * 2017-12-21 2020-04-28 주식회사 유엠아이옵틱스 항균 누점 플러그 및 그 제조방법
US20210145763A1 (en) * 2018-04-04 2021-05-20 Eye Co Pty Ltd Low thc hemp extract and method of treatment or prevention of an eye disease
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
DE102018208110A1 (de) 2018-05-23 2019-11-28 F. Holzer Gmbh Abgabekopf und Abgabevorrichtung zur dosierten Abgabe flüssiger Präparate sowie Verwendungsmöglichkeiten
CA3102410A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
CN111212642A (zh) * 2018-08-29 2020-05-29 奥古根有限公司 眼用组合物及使用方法
US20210008029A1 (en) * 2018-10-03 2021-01-14 Tathagata DUTTA Semisolid dosage forms for ophthalmic delivery of antioxidants
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
DE112020002226T5 (de) * 2019-05-03 2022-01-20 Mark Lobanoff Nahinfrarot-Beleuchtung für chirurgische Verfahren
CN114245737A (zh) * 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物
CN110384584A (zh) * 2019-06-28 2019-10-29 四川省一直牛健康管理有限公司 一款中西方芳香植物配伍的功能性眼罩及其制备方法
KR102498180B1 (ko) * 2019-09-11 2023-02-10 (주) 메드빌 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
CN111269161B (zh) * 2019-12-26 2022-03-08 深圳市真兴生物医药研究中心有限公司 厚朴酚与萝卜硫素拼接物及其制备方法和应用
WO2021183992A1 (en) * 2020-03-13 2021-09-16 Furst-Mcness Company Compositions and methods providing nutritional and other benefits having antiviral properties
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
JP7711090B2 (ja) 2020-04-17 2025-07-22 ボシュ + ロム アイルランド リミテッド 流体力学的に起動される防腐剤無添加分注システム
EP3919047A1 (de) * 2020-06-03 2021-12-08 AZAD Pharma AG Mikroemulsion zur behandlung des trockenen-augen-syndroms
CN116194082A (zh) * 2020-06-15 2023-05-30 犹他大学研究基金会 合成超长链多不饱和脂肪酸的视网膜生物利用度
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
WO2022018605A1 (en) * 2020-07-19 2022-01-27 Narayana Nethralaya Foundation A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
KR20230074759A (ko) * 2020-09-25 2023-05-31 가부시키가이샤 쓰보타 라보 드라이 아이의 예방제, 개선제 및 치료제
IT202000026236A1 (it) * 2020-11-04 2022-05-04 Iromed Group S R L Composizione oftalmica
MX2024009147A (es) * 2022-01-26 2024-08-06 Amarin Pharmaceuticals Ie Ltd Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas.
CN116253891B (zh) * 2022-08-22 2024-09-20 中南大学湘雅医院 Chta-dsb-da高分子载体及其载药纳米材料的制备和在眼科药物中的应用
KR102513994B1 (ko) * 2022-10-26 2023-03-24 김태윤 반려동물의 눈물 착색예방용 조성물
CN116196263A (zh) * 2023-02-23 2023-06-02 河南大学 一种含有干细胞提取物的护肤组合物及其制备方法
CN118477012B (zh) * 2024-05-07 2025-01-21 广州品域美妆创新科技有限公司 一种含胶原的抗皱紧致组合物及其在化妆品中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98747A0 (en) * 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
JPH08502759A (ja) * 1993-08-18 1996-03-26 アルコン ラボラトリーズ,インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
ES2256608T3 (es) 2003-04-09 2006-07-16 URSAPHARM ARZNEIMITTEL GMBH & CO. KG Dispensador de fluidos.
JP5292277B2 (ja) * 2006-03-31 2013-09-18 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
EP1985298A1 (de) * 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10045996B2 (en) * 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors

Also Published As

Publication number Publication date
CN104394859A (zh) 2015-03-04
EP2664329A1 (de) 2013-11-20
CA2873265A1 (en) 2013-11-21
EP2849741A2 (de) 2015-03-25
MX2014013884A (es) 2015-06-23
WO2013171204A2 (de) 2013-11-21
KR20150014966A (ko) 2015-02-09
JP2015521182A (ja) 2015-07-27
RU2014145440A (ru) 2016-07-10
AU2013261873A1 (en) 2014-12-04
HK1202427A1 (en) 2015-10-02
US20150139973A1 (en) 2015-05-21
WO2013171204A3 (de) 2014-01-09

Similar Documents

Publication Publication Date Title
WO2013171204A3 (de) Ophthalmologisches vehikelsystem
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
EP4371615A3 (de) Behandlung von amd mit aav sflt-1
MY171920A (en) Prevention and treatment of ocular conditions
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
HK1205461A1 (zh) 用於眼部传输治疗剂的组合物和方法
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
IN2014CN02972A (de)
BR112012015386B8 (pt) composição oftálmica tópica
EP4420722A3 (de) Modifizierte fibroblasten-wachstumsfaktoren zur behandlung von augenerkrankungen
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
EP3587392A8 (de) Nanostrukturierte formulierungen zur verabreichung von silibinin und anderen wirkstoffen zur behandlung von augenerkrankungen
BR112015019524A2 (pt) tratamento de combinação
MX2013008635A (es) Mejoras de y relacionadas con composiciones.